Sir David Amess
To ask the Secretary of State for Health, what recent discussions he has had with NHS England and NICE on the Cancer Drugs Fund consultation; and whether he discussed with those bodies whether proposals on the future of that fund would (a) increase and (b) restrict access to cancer medicines.

George Freeman

My Rt. hon. Friend the Secretary of State for Health has been kept informed as this work has been progressed.

Sir David Amess
To ask the Secretary of State for Health, what estimate his Department has made of the number of patients who will be able to access treatments for colorectal cancer on the NHS from April 2016.

George Freeman

Justin Madders
To ask the Secretary of State for Health, with reference to page 24 of the interim report of the Accelerated Access Review, published in October 2015, what steps he is taking to ensure that drugs that target the genetically validated targets (a) PCSK9 and (b) BCL2 are introduced into routine NHS care; and if he will make a statement.

George Freeman

Andrew Gwynne
To ask the Secretary of State for Health, with reference to page 15 of the interim report of the Accelerated Access Review, published October 2014, what recent discussions he has had on the implementation of new models of pricing and reimbursing drugs; when he anticipates implementing such new models; what discussions he has had with (a) his Department's officials and (b) external organisations on the applicability of such models to drugs targeting the genetically validated target PCSK9; and if he will make a statement.

George Freeman

Justin Madders
To ask the Secretary of State for Health, with reference to page 15 of the interim report of the Accelerated Access Review, published October 2014, what recent discussions he has had on the implementation of new models of pricing and reimbursing drugs; when he anticipates implementing such models; what discussions he has had with (a) his Department's officials and (b) external organisations on the applicability of such models to drugs targeting the genetically validated target PCSK9; and if he will make a statement.

George Freeman

Jim Shannon
To ask the Secretary of State for Health, when he expects the lung cancer drug Zykadia to be available on the NHS.

George Freeman

Zykadia (ceritinib) is licensed for use in the treatment of Zykadia (ceritinib) in the United Kingdom.

The National Institute for Health and Care Excellence (NICE) is currently appraising Zykadia for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Ben Howlett
To ask the Secretary of State for Health, whether the 100,000 Genomes project will be able to diagnose patients with a ring chromosome.

George Freeman

John Glen
To ask the Secretary of State for Health, what discussions NICE has had with the EU institutions on the proposed Joint Action 3 on health technology appraisals.

George Freeman

In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

John Glen
To ask the Secretary of State for Health, what discussions he has had with NICE on its policy on a European relative effectiveness assessment for new drugs.

George Freeman

In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

John Glen
To ask the Secretary of State for Health, what representations he has received from NICE on the potential merits of a European relative effectiveness assessment to inform health technology appraisals.

George Freeman

In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).